Benzodiazepines (Valium, Serepax, Xanax, Rivotril) — patient guide

Dr HB Lo does not routinely prescribe benzodiazepines. If you’re on one, this page is for you — understanding what you’re on, what to monitor, how to taper safely if that’s the plan. Initiation discussions happen with your specialist or referring GP. End-of-life palliative care and procedural sedation are separate clinical contexts and not covered here.

This page covers the AU-marketed benzodiazepine family. Your medicine belongs here if it is Valium, Antenex, Ducene, Serepax, Murelax, Normison, Temaze, Xanax, Kalma, Alprax, Ralozam, Rivotril, Paxam, Mogadon, Alodorm, or Ativan. Midazolam (Hypnovel) is used for procedural sedation and end-of-life care. Those are separate contexts and not covered here.

---

Find your medicine

Generic name	Common brand names	Strengths	How often	Schedule
Diazepam	Valium, Antenex, Ducene, generics	2 / 5 mg	Variable — long half-life often allows once daily at steady state	Schedule 4 — monitored
Oxazepam	Serepax, Murelax, generics	15 / 30 mg	3-4 times daily for acute anxiety	Schedule 4 — monitored
Temazepam	Normison, Temaze, Temtabs, generics	10 mg	Once nightly, short-term only	Schedule 4 — monitored
Alprazolam	Xanax, Kalma, Alprax, Ralozam	0.25 / 0.5 / 1 / 2 mg	2-3 times daily, usually specialist-supervised	Schedule 8 — controlled drug since 2014
Clonazepam	Rivotril, Paxam	0.5 / 2 mg	Once or twice daily	Schedule 4 — monitored
Nitrazepam	Mogadon, Alodorm	5 mg	Once nightly, short-term only	Schedule 4 — monitored
Lorazepam	Ativan	1 / 2.5 mg	2-3 times daily for acute anxiety	Schedule 4 — monitored

Schedule 4 means the medicine is prescription-only and is monitored by the TGA and AHPRA. In Victoria, every benzodiazepine script is captured by SafeScript real-time prescription monitoring. Other Australian states have equivalent systems with varying scope. Schedule 8 (alprazolam only) means the medicine is a controlled drug — every script is monitored and specialist supervision is the AU norm. None of this is a sign of wrongdoing — it is the safety scaffolding around a medicine class with real harm potential.

Looking for temazepam (Normison)? You are in the right place. Temazepam is sometimes grouped with Z-drugs (Stilnox, Imovane) in everyday general practice conversation because it is marketed for insomnia. Pharmacologically it is a benzodiazepine and shares the full benzodiazepine dependence and withdrawal profile. The sleep prescriptions page covers Z-drugs, suvorexant (Belsomra), and prolonged-release melatonin (Circadin) — not temazepam.

Closely related families. Sleep prescriptions (Z-drugs, suvorexant, melatonin) — combination-risk warning runs both ways. Gabapentinoids (gabapentin, pregabalin) — combination-risk warning runs both ways. Opioids — combination-risk warning runs both ways. SSRIs and SNRIs — the preferred agents for chronic anxiety and panic disorder.

---

Why HB does not routinely initiate

For the conditions benzodiazepines are most commonly prescribed for in general practice — chronic anxiety, chronic insomnia, and non-specific muscle pain — the long-term harm profile usually outweighs the long-term benefit. The reasons are well-documented:

• Tolerance develops within weeks. The dose that worked at the start typically gives less benefit over weeks to months, and dose escalation does not reliably restore the original effect.
• Physical dependence sets in after 2 to 4 weeks of regular use. The body adapts. Stopping abruptly causes a withdrawal syndrome that can include rebound anxiety, insomnia, agitation, sweating, tremor, nausea, and — in established users or higher doses — delirium or seizures. Withdrawal seizures are a medical emergency.
• Falls and fractures in older adults. Cochrane meta-analyses show a measurable rise in falls and fractures on benzodiazepines in people aged 65 and over (Cochrane review on falls prevention). Hip fracture is the most consequential outcome.
• Cognitive effects. Sedation, slowed thinking, impaired memory and concentration — particularly in the first weeks of use and after dose increases. In older adults, regular benzodiazepine use can mimic or amplify early dementia-type symptoms (Markota 2016).
• Combination-overdose death. Combining a benzodiazepine with an opioid painkiller, a Z-drug, a gabapentinoid, or alcohol causes additive sedation and slowed breathing. AU overdose deaths involving benzodiazepines plus opioids have been rising since 2016 (Roxburgh 2021).

For chronic anxiety, generalised anxiety disorder, and panic disorder, the gold-standard evidence-based interventions are CBT plus an SSRI or SNRI (NICE CG113). For chronic insomnia, the gold-standard intervention is CBT-I plus sleep hygiene (NICE NG201; Mitchell 2012).

This is not a judgement of any previous prescriber. Guidance has shifted. Many people were started on a benzodiazepine years or decades ago when the evidence base looked different, and the medicine has become part of the daily routine. The honest conversation now is about whether the original reason still applies, whether tolerance has set in, and whether a planned deprescribing pathway is the right next step.

---

Where short-term benzodiazepine use IS reasonable

There is a narrow set of clinical contexts where short-term benzodiazepine use is the right tool. These are not covered in depth on this patient page — they are clinical decisions made by the specialist or referring GP responsible for that part of your care — but for clarity:

• Severe acute anxiety crisis where non-pharmacological options have failed and specialist input is in place. Typically 2 to 4 weeks maximum, with the taper planned from the start.
• Medically supervised alcohol withdrawal — either as an inpatient or in a structured outpatient withdrawal programme. Benzodiazepines reduce the risk of withdrawal seizures and delirium tremens in this context.
• Status epilepticus and acute seizure termination — an emergency or hospital context. Parenteral lorazepam, midazolam, or diazepam.
• Specialist-initiated treatment of refractory panic disorder where SSRI or SNRI plus CBT has failed. Specialist-psychiatry supervision.
• Specialist-initiated treatment of refractory epilepsy — specialist-neurologist supervision (clonazepam as add-on).
• End-of-life palliative care symptom control — managed by a palliative care team. Separate clinical context, not covered here.
• Procedural sedation — anaesthetic or endoscopic settings, managed by an anaesthetist or proceduralist. Separate clinical context, not covered here.

Outside these contexts, the default is to look elsewhere first. That default reflects the evidence, not personal preference.

---

The basics

1. Never stop suddenly after established use. After 2 to 4 weeks or more of regular use, the body has adapted. Sudden cessation can cause withdrawal seizures and delirium. Always taper under medical supervision.
2. Never combine without your prescriber’s knowledge with opioid painkillers, Z-drugs (Stilnox, Imovane), gabapentinoids (pregabalin / Lyrica, gabapentin), other benzodiazepines, or alcohol. The combination is the main cause of benzodiazepine-related deaths in Australia.
3. Take it only as prescribed. Do not double up if you miss a dose. Do not borrow a benzodiazepine from a friend or family member.
4. Call 000 for marked drowsiness with slow or shallow breathing, blue lips, unresponsiveness — particularly after a combined dose with another sedating medicine or alcohol — or for any seizure, or for sudden swelling of face, lips, tongue, or throat.

Everything else — side effects, the combination warning in detail, the deprescribing pathway, the integrative angle — is below.

---

The combination warning — read this section

This is the single most important safety conversation about benzodiazepines in Australia today.

Combining a benzodiazepine with any of the following causes additive sedation and slowed breathing. AU overdose deaths involving benzodiazepines in combination with opioids have been rising since 2016 (Roxburgh 2021; Lloyd 2017 on the alprazolam-specific signal).

• Opioid painkillers — codeine (Panadeine Forte), tramadol (Tramal), tapentadol (Palexia), oxycodone (Endone, OxyContin), morphine (MS Contin), buprenorphine (Norspan, Subutex), fentanyl patches (Durogesic).
• Z-drugs (sleep tablets) — zolpidem (Stilnox), zopiclone (Imovane), suvorexant (Belsomra).
• Gabapentinoids — pregabalin (Lyrica), gabapentin (Neurontin). See the gabapentinoids page for the mirror-image warning.
• Other benzodiazepines — never combine two benzodiazepines without explicit prescriber instruction (substitution tapers are an exception and are supervised).
• Alcohol — in any meaningful amount on a day a benzodiazepine is taken. Also a per-se driving offence in every Australian state.
• Sedating antihistamines — promethazine (Phenergan), doxylamine (Restavit), diphenhydramine.
• Sedating antidepressants — particularly mirtazapine (Avanza) at sleep-aid doses, amitriptyline, doxepin.
• Antipsychotics — quetiapine (Seroquel), olanzapine (Zyprexa).
• Muscle relaxants — orphenadrine (Norflex), baclofen.
• Opioid substitution therapy — methadone, buprenorphine. Benzodiazepine prescribing in patients on opioid substitution therapy is an addiction-medicine specialist decision, not a routine GP decision.
• Medicinal cannabis containing THC — additive sedation and impairment.

Never combine without your prescriber’s explicit knowledge. Tell every doctor, dentist, surgeon, anaesthetist, and pharmacist what you are taking. Check before buying any over-the-counter sleep aid or sedating cold-and-flu remedy.

If you live with someone, it is reasonable to tell them what marked drowsiness with slow or shallow breathing looks like — pale or blue lips, very slow or shallow breathing, hard to rouse — and that the response is to call 000 immediately.

---

The alprazolam (Xanax) story — why it’s Schedule 8

Alprazolam was up-scheduled from Schedule 4 to Schedule 8 by the TGA on 1 February 2014. That move is rare. It was a response to the Australian data:

• Mortality signal — alprazolam appeared in fatal overdoses (often with opioids and other sedatives) at rates above the rest of the class (Lloyd 2017).
• Dependence signal — clinically significant dependence and difficulty tapering. Sharp withdrawal between scheduled doses.
• Diversion signal — alprazolam appearing on the AU black market in meaningful volumes.

The pharmacology has not changed. The short half-life of 6 to 12 hours produces sharp peaks and troughs. That drives intense reinforcement on dosing and intense withdrawal between doses. Of all the benzodiazepines in routine AU use, alprazolam carries the highest dependence and overdose-death signal.

Practical implications:

• Routine GP initiation of alprazolam is strongly discouraged in Australia.
• Specialist (RANZCP psychiatrist) supervision is the AU norm for any continuing script.
• Real-time prescription monitoring captures every alprazolam script across Australian states.
• The deprescribing pathway usually involves switching to a long-acting agent first (diazepam or clonazepam) to smooth the withdrawal curve. The slow taper comes after that.

---

Tap any section below to expand the detail.

How do they work?

Benzodiazepines bind to a specific site on the GABA-A receptor — the brain’s main inhibitory system. That binding enhances the action of GABA, the brain’s primary inhibitory neurotransmitter, slowing neural activity. The effect produces sedation, anxiolysis (anxiety reduction), muscle relaxation, and anticonvulsant activity — all four are different expressions of the same general “quietening” of neural firing.

The mechanism is shared across the class. The differences between the individual medicines on this page are how long the drug and its active metabolites stay in the body (half-life), how the body breaks the drug down (CYP3A4 oxidation versus glucuronidation), and which receptor subtypes the drug binds most strongly to (which influences whether sedation, anxiolysis, or anticonvulsant activity dominates).

The mechanism also explains the safety profile. Quietening neural firing across the brain produces predictable side effects — slowed thinking, slowed coordination, slowed reaction time, blunted memory formation, and (at higher doses or in combination with other CNS depressants) slowed breathing. The same mechanism explains why tolerance develops (the brain adapts to the constant GABA enhancement by reducing the number or sensitivity of GABA-A receptors) and why withdrawal looks the way it does (when the medicine is removed, the down-regulated receptor system is left under-active, producing the rebound anxiety, insomnia, agitation, tremor, and — in severe cases — seizures).

Side effects in detail

Common (usually mild, often dose-related)

• Sedation and drowsiness — common in the first week and after every dose increase. Do not drive or operate machinery until you know how the medicine affects you. Combination with other sedating medicines or alcohol amplifies the effect.
• Slowed thinking, impaired concentration — common, often improves with dose reduction. In older adults, can mimic or amplify early dementia-type symptoms.
• Anterograde amnesia — benzodiazepines can erase memory of conversations or events between taking the tablet and falling asleep. Do not take a benzodiazepine and then send important emails, sign documents, or drive.
• Unsteadiness and dizziness — particularly important in adults aged 65 and over because of the fall and fracture risk.
• Headache, dry mouth, mild nausea — usually settle.

Uncommon

• Disinhibition or paradoxical reaction — increased aggression, agitation, anxiety, or risk-taking behaviour rather than the expected calming effect. More common in adolescents, older adults, and people with personality disorder traits. Tell the prescriber immediately — the medicine should usually be stopped under taper.
• Mood changes — new or worsening depression, low mood, or thoughts of self-harm. Tell the prescriber immediately or contact Lifeline 13 11 14. Call 000 if safety is at risk right now.
• Skin rash, gastrointestinal upset, mild liver enzyme rise — uncommon.

Rare but serious — act quickly

• Severe withdrawal on abrupt cessation — delirium, seizures. Withdrawal seizures are a medical emergency. Call 000 for any seizure.
• Combination-overdose features — marked drowsiness with slow or shallow breathing, blue lips, hard to rouse, particularly after a dose taken with an opioid, Z-drug, gabapentinoid, or alcohol. Call 000.
• Angioedema — sudden swelling of face, lips, tongue, or throat. Stop the medicine and go to the emergency department.
• Severe allergic reaction — widespread rash, blistering, swelling, difficulty breathing. Stop the medicine and go to the emergency department.
• Marked confusion or delirium — particularly in older adults. Stop the medicine (under supervised withdrawal if established use) and seek urgent medical care.
• Falls with injury — particularly hip fracture in older adults. Urgent review.

Drugs, food, and alcohol

The combination warning above is the most important interaction conversation for this class. This section covers the rest.

• Strong CYP3A4 inhibitors with diazepam and alprazolam — azole antifungals (fluconazole, itraconazole, voriconazole, ketoconazole), macrolide antibiotics (clarithromycin, erythromycin — azithromycin to a lesser extent), protease inhibitors (ritonavir), grapefruit juice in large quantities. These raise diazepam and alprazolam levels, sometimes sharply. Oxazepam and lorazepam (glucuronidation only) are not affected. Tell your GP and pharmacist about every new prescription, including short antibiotic and antifungal courses.
• Strong CYP3A4 inducers — rifampicin, carbamazepine, phenytoin, St John’s wort. These reduce diazepam and alprazolam levels. Oxazepam and lorazepam are not affected.
• Other sedating medicines — see the combination warning above.

Food. No specific food restrictions for most benzodiazepines. Grapefruit juice in large quantities can raise diazepam and alprazolam levels (CYP3A4 inhibition); occasional small servings are unlikely to matter.

Alcohol. Avoid completely on any day a benzodiazepine is taken. Additive sedation, additive impairment, additive respiratory-depression risk, and a per-se driving offence in every Australian state. If alcohol is part of your routine, raise it with the prescriber rather than working around it on your own.

Cannabis and medicinal cannabis containing THC. Additive sedation and impairment. Tell the prescriber.

Generic substitution at the pharmacy. Generic benzodiazepines are bioequivalent to the brand-name versions. If the pharmacist offers a generic, it is fine to take. The dose is the same.

The deprescribing pathway — how to come off safely

Never stop a benzodiazepine suddenly after established use. The withdrawal syndrome can be severe and includes — in addition to rebound anxiety and insomnia — agitation, sweating, tremor, perceptual disturbance, and (in established users or higher doses) delirium and seizures. Withdrawal seizures are a medical emergency. People have died from unsupervised benzodiazepine withdrawal.

The deprescribing pathway is a planned, supervised, gradual reduction. The Australian primary resource is NPS RADAR. The Wales deprescribing protocol (Wales Therapeutics and Toxicology Centre) and the Maudsley Deprescribing Guidelines (Horowitz and Taylor 2024) lay out the current best-practice taper protocols.

Typical supervised taper:

• Short-term users (under 2-4 weeks) — usually can stop with a brief step-down over 1-2 weeks.
• Established users (months to years) — reduce the daily dose by 10-25% every 2-4 weeks. Slower for higher doses. Slower for longer duration of use. Slower in people with a history of withdrawal symptoms.
• Very long-term users (years to decades) or higher doses — the taper may be measured in many months to a year or more, with reductions as small as 5-10% per step in the final stages.

Substitution to a long-acting agent first. For short-acting benzodiazepines (particularly alprazolam, and to a lesser extent temazepam and oxazepam in some patients), the prescriber will often switch to an equivalent dose of diazepam or clonazepam before tapering. The long half-life smooths the withdrawal curve — fewer inter-dose troughs, fewer reinforcement peaks.

What to expect during the taper:

• Rebound anxiety, insomnia, irritability, sweating, mild tremor in the first 1-2 weeks after each dose drop — usually settling.
• Wave-and-trough pattern — symptoms often spike for a few days after a dose drop and then settle before the next drop.
• The temptation to “just stop” or to dose-escalate during a difficult patch — both are predictable and both should be discussed with the prescriber rather than acted on alone.

Plan the taper around a low-stress period if possible. Run CBT and CBT-I behavioural strategies in parallel. Reconnexion is the AU patient-support service designed for exactly this conversation — peer support, counselling, and information specifically for people coming off benzodiazepines.

This is a planned conversation, not an improvised one. Book a dedicated review with your GP before changing the dose.

Withdrawal red flags — when to call 000

Call 000 immediately for:

• Any seizure. Withdrawal seizures are a medical emergency.
• Marked confusion, hallucinations, severe agitation, or delirium.
• Marked drowsiness with slow or shallow breathing — particularly if combined with an opioid, Z-drug, gabapentinoid, or alcohol.
• Sudden swelling of face, lips, tongue, or throat.

Contact your GP urgently (same day) for:

• Withdrawal symptoms that are severe, persistent, or worsening after a dose drop.
• New or worsening thoughts of suicide or self-harm. Lifeline 13 11 14 is available 24 hours.
• Paradoxical reaction — increased aggression, agitation, or anxiety on the medicine.
• Near-miss or fall.
• Marked memory or cognitive change, particularly in older adults.

Contact your GP within a few days for:

• Persistent insomnia, anxiety, or low mood that is not settling.
• A pattern that suggests tolerance — the medicine is not working the way it used to.
• A pattern that suggests dependence — anxiety about running out, taking the medicine earlier than scheduled, considering a dose increase without prescriber agreement.
• Concerns about combination with any new medicine, supplement, or alcohol pattern.

Older adults — the fall conversation

Benzodiazepines cause a measurable rise in falls and fractures in people aged 65 and over — confirmed across Cochrane meta-analyses. The mechanism is the predictable sedation, dizziness, and unsteadiness of the class layered onto an age group with already-reduced balance reserve. Hip fracture is the most consequential outcome.

In older adults, regular benzodiazepine use can also mimic or amplify early dementia-type symptoms — slowed thinking, memory difficulty, confusion (Markota 2016). What looks like cognitive decline sometimes resolves on careful deprescribing.

The defensible approach in people aged 65 and over:

• Planned deprescribing conversation. If you are on a long-acting benzodiazepine (diazepam, clonazepam, nitrazepam) or any benzodiazepine at all, the question to discuss with the prescriber is whether a planned taper is appropriate.
• If a benzodiazepine must be used, prefer oxazepam or lorazepam. Intermediate half-life, no active metabolite, glucuronidation only — these do not accumulate the way diazepam, clonazepam, and nitrazepam do.
• Lower starting dose, slower titration.
• Home-hazard review. Loose rugs, poor lighting at night, bathroom rails, clear paths between bed and bathroom.
• Walking-aid review. If a stick or frame would help, this is the moment.
• Vitamin D check — supports bone strength if a fall does happen.
• Bone-density consideration — particularly in women over 65 and men over 70 with other risk factors.
• Avoid stacking sedating medicines. Sedating antihistamines (Restavit, Phenergan), sedating antidepressants (mirtazapine, amitriptyline), Z-drugs (Stilnox, Imovane), opioids — each adds to the fall and confusion risk.
• CBT-I instead of, or alongside, a benzodiazepine hypnotic. Effective at any age. No fall signal. No dependence signal. Free digital tools through the Sleep Health Foundation Australia.

If you have had a near-miss or a fall on a benzodiazepine, that is a reason to review urgently rather than wait for the next routine appointment.

Driving — Austroads standards

Even at therapeutic doses, benzodiazepines impair reaction time, coordination, and judgement. The Austroads Assessing Fitness to Drive standards — the AU national clinical reference for fitness to drive — require commercial drivers (truck, bus, taxi, rideshare) to disclose regular benzodiazepine use to the driver licensing authority and recommend medical review before driving. Private drivers are advised to be cautious.

Combining a benzodiazepine with alcohol is a per-se driving offence in every Australian state — meaning the offence applies regardless of whether actual impairment is demonstrated.

Practical safety steps:

• Do not drive until you know how the medicine affects you. After every dose increase, the question reopens.
• Do not drive on any day you have had alcohol if you are on a benzodiazepine.
• Do not take a benzodiazepine hypnotic (temazepam, nitrazepam) and then drive. Anterograde amnesia is an additional risk — the medicine can erase memory of events between dosing and falling asleep.
• If you drive for a living, tell your prescriber. The fitness-to-drive conversation is a routine part of the consultation, not a punishment.

Pregnancy and breastfeeding

Benzodiazepines are AU pregnancy category C — they cross the placenta and are associated with neonatal withdrawal syndrome, neonatal sedation, and (with first-trimester exposure) a small absolute increase in some birth defects. The first trimester is the most sensitive window.

• Planning a pregnancy — tell the prescriber before trying to conceive. For most indications (anxiety, insomnia) a planned taper and transition to a pregnancy-safer alternative is the right path. For others (rare specialist contexts), continuation at the lowest effective dose may be appropriate.
• Already on a benzodiazepine and just found out you are pregnant — contact your GP and obstetric team as soon as possible. Do not stop the medicine suddenly. For an established user, sudden cessation risks withdrawal seizure, which is dangerous for both you and the pregnancy. The plan is made together with your team.
• Third-trimester exposure — neonatal withdrawal syndrome and neonatal sedation are documented. The obstetric and neonatal teams will plan accordingly.
• Breastfeeding — benzodiazepines transfer into breast milk and can cause sedation, poor feeding, and reduced weight gain in the infant. The decision to continue or switch is made case by case. Shorter-acting agents (oxazepam, lorazepam) and lower doses are often preferred where a benzodiazepine must be continued.

If a younger family member or housemate is curious about your tablets

Benzodiazepines — and alprazolam in particular — carry a misuse signal in Australia, and shared-household access is a real route to harm.

• Store the medicine out of easy reach. Not on the kitchen counter, not in a handbag left on a hall table.
• Do not share your script. A benzodiazepine handed to a friend “for their anxiety” or “to help them sleep” can sedate, cause respiratory depression, and — particularly with alcohol or another sedating drug — kill.
• If a tablet goes missing, tell the prescriber. It is a brief, non-judgemental conversation and is the right thing to do.
• If you have a young child in the home or visiting, a child-resistant container is essential.
• If a household member is struggling with substance use, talk to the prescriber about secure storage — a small medication safe is inexpensive and removes a real risk.

Cost

Most benzodiazepines are on the PBS for their on-label indications. From 1 January 2026, the PBS co-payment is:

• General patient — up to $25.00 per script.
• Concession card holder — up to $7.70 per script.

By medicine:

• Diazepam, oxazepam, temazepam, nitrazepam, lorazepam, clonazepam — PBS-listed, mostly without authority restrictions. Standard co-payment.
• Alprazolam (Xanax, Kalma, Alprax, Ralozam) — PBS-listed with S8-controlled-drug prescribing requirements. Real-time prescription monitoring captures every script.

Generic versions cost the same as brand-name versions at PBS pricing and work the same. Confirm with your pharmacist — they can show you the exact price for your script and tell you the cheapest option.

(MBS / PBS items verified 2026-05-25 via WebSearch — workspace egress to mbsonline.gov.au + pbs.gov.au still blocked; spot-check confirms current.)

---

The integrative view

The integrative angle on anxiety and insomnia is substantial — arguably more substantial than for any other medication class on this site — because the foundational interventions are the primary therapy, with medicine as at most a short-term adjunct.

Two principles. First — for chronic anxiety and chronic insomnia, the durable improvement comes from changes the medicine cannot make on its own. Second — many people on long-standing benzodiazepine scripts are running on a workaround for an underlying issue (untreated sleep apnoea, untreated thyroid disease, perimenopausal vasomotor symptoms, chronic pain, untreated depression, alcohol use, caffeine load, screen exposure, shift-work pattern, financial stress, relationship stress, unmanaged work demands) that the medicine has masked rather than addressed.

Strong evidence — these reliably help

• CBT for chronic anxiety and panic disorder. The gold-standard evidence-based intervention. Superior to medication alone on long-term outcomes (NICE CG113). Available through a Mental Health Care Plan under Better Access — ten Medicare-rebated psychology sessions per calendar year. Smiling Mind, Calm, and the Black Dog Institute online CBT programmes are free or low-cost adjuncts.
• CBT-I for chronic insomnia. The gold-standard evidence-based intervention. Superior to medication on long-term outcomes (Mitchell 2012; NICE NG201). Durable improvement after treatment ends. No medication dependence. Available as free digital tools through the Sleep Health Foundation Australia and through psychologist referral under a Mental Health Care Plan.
• Sleep hygiene foundation. Consistent wake time every day including weekends. Dark, cool, quiet bedroom. Blue-light reduction from screens 2 hours before bed. Caffeine cessation after midday. Alcohol moderation. Morning rather than evening exercise where possible.
• Treating upstream drivers. Sleep apnoea workup if you snore loudly, have witnessed pauses, or wake unrefreshed. Thyroid screen if any anxiety, sleep, or mood pattern that fits hyperthyroidism. Perimenopausal vasomotor symptom management. Chronic pain plan. Treatment of any underlying depression. Reducing alcohol, caffeine, screen exposure, and unsustainable work demands.
• Avoiding alcohol. Additive sedation. Additive impairment. Additive respiratory-depression risk. Per-se driving offence with a benzodiazepine.

Moderate evidence — likely helpful

• Mindfulness, body-scan meditation, progressive muscle relaxation, slow nasal breathing at around 6 breaths per minute. Components of CBT and stress-reduction programmes that can be practised independently of formal therapy (Smiling Mind, Calm, Insight Timer apps). Reduce the autonomic arousal that maintains chronic anxiety and chronic insomnia.
• Magnesium glycinate 300-400 mg in the evening. Modest evidence for sleep architecture, smooth muscle relaxation, and anxiety symptom relief. The glycinate form is better tolerated than oxide or citrate. Cheap, low harm. Avoid in advanced kidney disease without medical advice.
• L-theanine 200 mg. Anxiolytic effect without sedation. Some evidence for reduced anxiety and improved subjective sleep quality. Useful where racing thoughts are the dominant barrier to sleep onset.
• Ashwagandha 300-600 mg standardised extract. Modest evidence for chronic stress and anxiety symptoms in adults. Avoid in autoimmune thyroid disease without specialist input — potential thyroid-stimulating effect. Talk to your GP and pharmacist before starting — interactions with sedating medicines and thyroid medicines are possible.
• Vagal-tone work. Slow nasal breathing at around 6 breaths per minute, cold-water face immersion, humming. Particularly relevant where panic or anticipatory anxiety is the dominant pattern.
• Exercise. Aerobic and resistance training — modest direct anxiolytic effect, larger indirect effect via sleep, mood, and stress tolerance.

Limited or emerging evidence

• Iron and ferritin testing if restless-legs symptoms are part of the sleep complaint. Low ferritin (under 75 ng/mL, even within the lab-normal range) is associated with restless legs and can be addressed without a sedative.
• Vitamin D adequacy. Emerging evidence for a relationship between vitamin D deficiency and sleep quality and mood. Supplement if a blood test shows deficiency.
• Valerian, chamomile, lavender aromatherapy. Mild herbal options for sleep and anxiety. Modest evidence. Tell the prescriber what you are taking — valerian can interact with sedating medicines.

Specific to being on a benzodiazepine

• Run CBT or CBT-I in parallel from day one of any plan to come off. Free digital tools through the Sleep Health Foundation. Psychology under Better Access. The taper is easier with the underpinning in place.
• Address the upstream driver. Sleep apnoea, thyroid, perimenopause, chronic pain, depression, alcohol, caffeine, screens, shift work, stress load.
• Avoid stacking sedating medicines and supplements. Anything with a CNS-depressant action adds to the load — sedating antihistamines, sedating antidepressants, Z-drugs, opioids, alcohol, high-dose magnesium combined with sedating herbs, medicinal cannabis containing THC.
• Plan the taper as a project, not an improvisation. Reconnexion is the AU patient-support service designed for exactly this conversation. NPS RADAR and the Wales deprescribing protocol are the operational templates.

Earning a lower dose, or coming off

For most non-specialist benzodiazepine prescriptions, the realistic goal is: stabilise → plan the deprescribing pathway → substitute to a long-acting agent if needed → slow taper → CBT or CBT-I as the durable underpinning → off entirely, with the upstream driver addressed.

This is a planned process, not a “see how it goes” process. The conversation about reducing the dose, and what the off-medicine plan looks like, is a planned appointment — typically with the prescriber who initiated, with input from CBT or CBT-I therapy in parallel, and with Reconnexion peer support where helpful.

If you are on a benzodiazepine for a specialist context (refractory epilepsy under neurology, refractory panic under psychiatry, end-of-life palliative care, procedural sedation), that is different — the medicine is continued under specialist supervision, and the conversation is about optimisation rather than withdrawal.

---

Track these between now and your next visit

• Dose and timing — exactly what you are taking, when, and whether you have missed or doubled up any doses.
• Anxiety, sleep, or symptom scores — a simple 0-10 rating, same time each day, takes 5 seconds.
• Drowsiness or unsteadiness — when in the day, how marked, any near-misses or falls.
• Memory and concentration — note any change, particularly in older adults.
• Mood — note any change, particularly any new low or any thought of self-harm. If safety is at risk, contact Lifeline 13 11 14 or call 000.
• Anything new you have started — over-the-counter medicines, supplements, alcohol changes, other prescribers’ prescriptions, particularly antibiotics or antifungals if you are on diazepam or alprazolam.
• Any pattern that suggests tolerance or dependence — the medicine is not working the way it used to, anxiety about running out, taking the medicine earlier than scheduled, considering a dose increase without prescriber agreement.

Bring the list to the review appointment.

---

This is general information, not personal medical advice. Every patient is different. Decisions about your benzodiazepine — which one, what dose, when to stop, what to combine with, how to taper — are made with the doctor who prescribed it. If anything on this page appears to contradict advice from your treating doctor, follow your doctor; they have context about your situation that this page cannot.

Reading this page does not establish a doctor-patient relationship with Dr Hoebing Lo. If you are not a current patient, please discuss your medicines with your own GP, specialist, or pharmacist.

About the integrative content. The CBT, CBT-I, sleep hygiene, nutrient, and complementary recommendations on this page summarise current published research. Effect sizes are approximations from clinical studies — individual response varies, and real-world results are commonly smaller than trial results because day-to-day life differs from study conditions. Supplements and herbal products are not interchangeable with prescribed medication and can interact with it. Talk to your doctor and pharmacist before starting any new supplement, herbal product, or significant change in diet.

Currency. This page reflects clinical practice as of the last-reviewed date. Medicine evolves; specific details may date between reviews. Pricing shown is indicative; confirm with your pharmacist. PBS listings, authority restrictions, and Schedule classifications change — confirm at the time you fill the script.

No commercial relationships. Dr Hoebing Lo has no financial or commercial relationship with the manufacturer of any medicine, brand, or supplement mentioned on this page.

Emergencies. If you have sudden swelling of face, lips, tongue, or throat; difficulty breathing; marked drowsiness with slow or shallow breathing; seizure; thoughts of suicide or self-harm; or severe dizziness or fainting — call 000 or go to your nearest emergency department. For mental-health crisis support, Lifeline 13 11 14 is available 24 hours.